Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break MomentInvestors Business Daily • 09/28/23
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingGlobeNewsWire • 09/27/23
CRISPR Therapeutics: CEO Targets $25bn Valuation - Exa-Cel Approval Is First StepSeeking Alpha • 09/20/23
Crispr Therapeutics: The Chance To Load Up Is Finally Here (Technical Analysis)Seeking Alpha • 09/08/23
CRISPR Therapeutics AG (CRSP) Presents at Citi's 18th Annual BioPharma Conference TranscriptSeeking Alpha • 09/06/23